Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease
Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis
Objective: To investigate the pattern of comorbidities and comedications in PSP patients compared to age-matched controls. Background: Although progressive supranuclear palsy (PSP) is usually diagnosed…The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial
Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis
Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…Changes in artistic style and Parkinson’s Disease
Objective: We present a Parkinson’s disease (PD) patient in whom dopamine agonists produced a dramatic change in her art style and production, and the subsequent…15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation
Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial
Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 32
- Next Page »